Department of Internal Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8606, Japan.
Int J Hematol. 2010 Jan;91(1):140-5. doi: 10.1007/s12185-009-0467-2. Epub 2009 Dec 25.
The availability of highly active anti-retroviral therapy (HAART) has greatly improved the outcome of human immunodeficiency virus type-1 (HIV-1) infection and disease. We report here on a case of an HIV-1-seropositive patient with acute myelogenous leukemia who underwent a successful allogeneic unrelated bone marrow transplantation following HAART. A 40-year-old Japanese HIV-seropositive man underwent allogeneic unrelated bone marrow transplantation using a myeloablative pretransplant-conditioning regimen. Neutrophil engraftment occurred on day +18, and donor chimerism was achieved on day +27. During pre- and post- transplantation, the HAART was not interrupted. Over 1 year after transplantation, the patient is alive and in continuous complete remission with undetectable levels of HIV-1 RNA. HAART can lead to a successful hematopoietic stem cell transplantation without severe opportunistic infections.
高效抗逆转录病毒疗法（HAART）的出现极大地改善了人类免疫缺陷病毒 1 型（HIV-1）感染和疾病的预后。我们在此报告了一例 HIV-1 血清阳性的急性髓系白血病患者，他在接受 HAART 后成功地进行了异基因无关骨髓移植。一名 40 岁的日本 HIV 血清阳性男子接受了使用清髓性预处理方案的异基因无关骨髓移植。中性粒细胞植入发生在+18 天，+27 天时达到供者嵌合状态。在移植前和移植后，HAART 没有中断。移植后 1 年多，患者仍然存活，并处于持续完全缓解状态，HIV-1 RNA 检测不到。HAART 可导致造血干细胞移植成功，而不会发生严重的机会性感染。
